PurposeTo characterize demographic, disease, and cancer outcomes of men on active surveillance (AS) at a safety-net hospital and characterize those who were lost to follow-up (LTFU).MethodsFrom January 2004 to November 2014, 104 men with low-risk prostate cancer (PCa) were followed with AS at Zuckerberg San Francisco General Hospital (ZSFG). Criteria for AS have evolved over time; however, patients with diagnostic prostate-specific antigen (PSA) 10ng/mL or less, clinical stage T1/2, biopsy Gleason score 3 + 3 or 3 + 4, 33% or fewer positive cores, and 50% or less tumor in any single core were potentially eligible for AS. Men were longitudinally followed with a PSA or digital rectal examination or both every 3 to 6 months, and repeat prostat...
Background: Men with prostate cancer on active surveillance (AS) are advised to follow strict follow...
BACKGROUND: Active surveillance (AS) is increasingly recognized as a recommended treatment option fo...
Objective: To estimate the increase in prostate cancer mortality (PCM) and the reduction in overtrea...
Objective: To report the outcomes of active surveillance (AS) for low-risk prostate cancer (PCa) in ...
BackgroundActive surveillance followed by selective treatment for men who have evidence of disease p...
Purpose: Active surveillance to manage prostate cancer provides an alternative to immediate treatmen...
Background: Active surveillance (AS) is commonly used for men with low-risk prostate cancer (PCa). W...
PurposeActive surveillance to manage prostate cancer provides an alternative to immediate treatment ...
PurposeActive surveillance (AS) is an option for the initial management of early-stage prostate canc...
Background: Active surveillance (AS) as a treatment option for low risk prostate cancer is gaining r...
PurposeActive surveillance represents a strategy to address the overtreatment of prostate cancer, ye...
BACKGROUND: This study assessed the use of active surveillance in men with low-risk prostate cancer ...
Background. Men with a low-risk prostate cancer (PCa) should consider observation, particularly acti...
Background: In order to prevent over treatment of prostate cancer and significant adverse effects af...
Purpose Active surveillance represents a strategy to address the overtreatment of prostate cancer, y...
Background: Men with prostate cancer on active surveillance (AS) are advised to follow strict follow...
BACKGROUND: Active surveillance (AS) is increasingly recognized as a recommended treatment option fo...
Objective: To estimate the increase in prostate cancer mortality (PCM) and the reduction in overtrea...
Objective: To report the outcomes of active surveillance (AS) for low-risk prostate cancer (PCa) in ...
BackgroundActive surveillance followed by selective treatment for men who have evidence of disease p...
Purpose: Active surveillance to manage prostate cancer provides an alternative to immediate treatmen...
Background: Active surveillance (AS) is commonly used for men with low-risk prostate cancer (PCa). W...
PurposeActive surveillance to manage prostate cancer provides an alternative to immediate treatment ...
PurposeActive surveillance (AS) is an option for the initial management of early-stage prostate canc...
Background: Active surveillance (AS) as a treatment option for low risk prostate cancer is gaining r...
PurposeActive surveillance represents a strategy to address the overtreatment of prostate cancer, ye...
BACKGROUND: This study assessed the use of active surveillance in men with low-risk prostate cancer ...
Background. Men with a low-risk prostate cancer (PCa) should consider observation, particularly acti...
Background: In order to prevent over treatment of prostate cancer and significant adverse effects af...
Purpose Active surveillance represents a strategy to address the overtreatment of prostate cancer, y...
Background: Men with prostate cancer on active surveillance (AS) are advised to follow strict follow...
BACKGROUND: Active surveillance (AS) is increasingly recognized as a recommended treatment option fo...
Objective: To estimate the increase in prostate cancer mortality (PCM) and the reduction in overtrea...